NCAN and metabolic dysfunction-associated steatotic liver disease: Phewas analysis revealed that targeting CSPG3 shares similar effects with targeting GCKR. Consequently, CSPG3 has emerged as a promising therapeutic target for HCC in the context of NAFLD and alcoholic cirrhosis, warranting further research to investigate its role in liver diseases.